Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy
about
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsPrecision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?Genotyping panel for assessing response to cancer chemotherapy.A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidationStudy protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab vAssociation between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimensPharmacogenomics in early-phase clinical developmentEvaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line SettingComprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System.Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.A pharmacogenomics primer.Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28.Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.Interindividual differences in response to plant-based diets: implications for cancer risk.PhRMA white paper on ADME pharmacogenomics.Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.Novel inhibitors in development for hepatocellular carcinoma.Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI.Transcriptional regulation of human UDP-glucuronosyltransferase genes.Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.Pharmacogenomics: Time to re-think its role in Precision Medicine.Primary care physicians' concerns about offering a genetic test to tailor smoking cessation treatment.DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.
P2860
Q24651239-3F74D664-A973-4351-A302-74C78A0376DAQ26764984-4E40FF41-1FF4-4A59-91D8-7A7BA7913111Q26795742-633A25E2-76F7-43BC-9DC6-54A9C8C6740FQ33343095-6E57C916-E36F-4650-9553-44C92227DEE6Q33861874-00152826-F4F9-4CE5-A80E-446A000035C4Q34547844-851D2078-5051-4B57-9E07-735FADE79CB7Q34629650-1941EBB9-43FB-42B2-8689-002F6519BF18Q34632966-D6347BE6-D539-4660-9FA2-8788ACA9EC87Q35887458-E309BFC2-F39A-4C2D-BC8D-9FCBFF89B299Q36001208-56F0659F-38F3-4339-B6CE-94C7B5DC7BDCQ36115752-2C30B151-8B7E-4EB2-9172-516D325D4F63Q36132293-0FCB9A51-BCA2-49F2-90CC-65199947D52CQ36427498-E2BF0105-68DA-4A75-8811-3013135B1110Q36745692-46BD95F1-ABB2-4C1E-AC40-E9E2B3CD6354Q36892799-7D0A46ED-116B-4AAD-8823-4E3E80D70F3EQ36896796-CFC361A0-83C7-449A-9BA3-038C1E1BD384Q36944278-8003F52F-BC5E-4D7F-A596-BCF0FECE5386Q37091425-037E71B7-DC24-4880-A3BE-077CE19B395EQ37179160-771C533B-DAC3-4667-9F28-6F2DBDFE186FQ37182212-0338CF0A-0DCE-437B-8DD6-516014A2E8BFQ37312970-FA8BFF9C-499A-4DA9-8D60-8DF775F58C03Q37352037-1F3478D4-B953-44A0-9698-C281B54CBC32Q37725994-92A147E4-E77D-4298-997C-A0F897962932Q37959718-CFB41279-0C7D-484C-A170-008FBBA86D15Q37990054-94F4C5EC-33B6-4A1C-A025-E815955A64A2Q38073827-7413D3E1-8648-41F2-A62E-B8012874B3A5Q38184582-EA074151-76CF-4F53-A874-B3EF20FDAB83Q38233043-67DFFA1F-C9B7-40BB-B573-F5C14C873103Q38261875-8326D2E3-8665-426E-A591-2D833B06A9D1Q38998279-3D650CC3-5767-453D-BBDB-3554ED2A5F09Q39891547-4DDB89EB-622A-456E-A3F2-AEC89C32910AQ42659855-C1F8DFCA-3294-4776-98FE-944D556CA4C9Q43268896-C5175D9E-2E1B-451B-8DC3-8109AD4D1369Q43879300-E405A8D1-250D-4479-9000-6DFA1619D032Q46605316-E7F7AB20-5F03-40E2-AF63-A456949269AEQ48617362-858123C4-2834-458E-AB88-56852AFEFB42Q50039487-03840EE8-BCBB-434C-A35B-5C18211D4D07Q50147809-2A19F28E-1864-4362-8162-A832BEEA6A28Q51895884-0DC07BF7-EB99-4A5D-9710-833EC793A975Q52682270-65EC29FB-79B3-4909-8099-C3CABCB107D2
P2860
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@ast
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@en
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@nl
type
label
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@ast
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@en
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@nl
prefLabel
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@ast
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@en
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@nl
P356
P1476
Uridine diphosphate glucuronos ...... mics arrives in cancer therapy
@en
P2093
Peter J O'Dwyer
Robert B Catalano
P304
P356
10.1200/JCO.2006.07.3031
P407
P577
2006-10-01T00:00:00Z